Literature DB >> 12958314

Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists.

John O Trent1, Zi-xuan Wang, James L Murray, Wenhai Shao, Hirokazu Tamamura, Nobutaka Fujii, Stephen C Peiper.   

Abstract

CXCR4 is a G protein-coupled receptor (GPCR) that has multiple critical functions in normal and pathologic physiology that include regulation of the metastatic behavior of mammary carcinoma, and utilization as a coreceptor for infection by T-tropic strains of human immunodeficiency virus-1. Molecular dynamic simulations of the rhodopsin-based homology model of CXCR4 were performed in a solvated lipid bilayer to reproduce the microenvironment of this integral membrane protein. The amino acids in CXCR4 necessary for interaction with an inverse agonist, T140, and a weak partial agonist, AMD3100, identified by alanine scanning mutants, were spatially consistent when computationally docked. Whereas T140 binds residues in extracellular domains and regions of the hydrophobic core proximal to the cell surface, amino acids in the central hydrophobic core are critical to binding of AMD3100. The physical localization of T140 binding to CXCR4 by biochemical analyses corroborated the molecular and computational approaches. The structural basis for the interaction of T140 and AMD3100 with CXCR4 confirms that the mechanisms used by these agents are different. This complementary utilization of molecular, physical, and computation analysis provides a powerful approach to elucidate GPCR conformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958314     DOI: 10.1074/jbc.M307850200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.

Authors:  Stéphanie Gravel; Camille Malouf; Philip E Boulais; Yamina A Berchiche; Shinya Oishi; Nobutaka Fujii; Richard Leduc; Daniel Sinnett; Nikolaus Heveker
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

2.  Molecular dynamics simulations of bovine rhodopsin: influence of protonation states and different membrane-mimicking environments.

Authors:  Birgit Schlegel; Wolfgang Sippl; Hans-Dieter Höltje
Journal:  J Mol Model       Date:  2005-10-25       Impact factor: 1.810

3.  CCR5 interactions with the variable 3 loop of gp120.

Authors:  Kelby B Napier; Zi-xuan Wang; Stephen C Peiper; John O Trent
Journal:  J Mol Model       Date:  2006-05-24       Impact factor: 1.810

4.  Probing a model of a GPCR/ligand complex in an explicit membrane environment: the human cholecystokinin-1 receptor.

Authors:  Jérôme Hénin; Bernard Maigret; Mounir Tarek; Chantal Escrieut; Daniel Fourmy; Christophe Chipot
Journal:  Biophys J       Date:  2005-12-02       Impact factor: 4.033

Review 5.  Toll gates to periodontal host modulation and vaccine therapy.

Authors:  George Hajishengallis
Journal:  Periodontol 2000       Date:  2009       Impact factor: 7.589

Review 6.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

7.  Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.

Authors:  Joeri Kuil; Tessa Buckle; Hushan Yuan; Nynke S van den Berg; Shinya Oishi; Nobutaka Fujii; Lee Josephson; Fijs W B van Leeuwen
Journal:  Bioconjug Chem       Date:  2011-04-19       Impact factor: 4.774

8.  Potential of CXCR4/CXCL12 Chemokine Axis in Cancer Drug Delivery.

Authors:  Yan Wang; Ying Xie; David Oupický
Journal:  Curr Pharmacol Rep       Date:  2016-01-04

9.  Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Authors:  Samvel R Mkrtchyan; Ruben M Markosyan; Michael T Eadon; John P Moore; Gregory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Computer-based design of novel HIV-1 entry inhibitors: neomycin conjugated to arginine peptides at two specific sites.

Authors:  Alexander Berchanski; Aviva Lapidot
Journal:  J Mol Model       Date:  2008-12-05       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.